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Ewing’s sarcoma is a highly aggressive pediatric tumor of bone that usually contains the characteristic chromosomal translocation
t(11;22)(q24;q12). This translocation encodes the oncogenic fusion protein EWS/FLI, which acts as an aberrant transcription
factor to deregulate target genes necessary for oncogenesis. One key feature of oncogenic transformation is dysregulation of cell
cycle control. It is therefore likely that EWS/FLI and other cooperating mutations in Ewing’s sarcoma modulate the cell cycle to
facilitate tumorigenesis. This paper will summarize current published data associated with deregulation of the cell cycle in Ewing’s
sarcoma and highlight important questions that remain to be answered.
1. Introduction
First described by James Ewing in 1921, Ewing’s sarcoma is
characterized as a highly aggressive, undifferentiated tumor
of the bone [1]. Although it is the second most common
primary bone tumor in children and adolescents, Ewing’s
sarcoma can also develop in extraosseous sites as a soft-
tissue malignancy [2, 3]. The etiology of Ewing’s sarcoma
remains unknown, but there appears to be a predominance
of cases within the Caucasian population, with males being
slightly more susceptible than females [3, 4]. This disease is
highly invasive with approximately one-fourth of all Ewing’s
sarcoma patients presenting with metastases at the time of
diagnosis [2, 5]. Current treatment methods include surgery,
radiation, and systemic chemotherapy [6]. Despite such an
aggressive regimen, the 5-year disease-free survival rate for
patients with localized Ewing’s sarcoma is only 60–70% and
that for individuals presenting with metastases drops to a
mere 30% [5, 7].
Approximately 85% of Ewing’s sarcoma tumors harbor
the reciprocal translocation t(11;22)(q24;q12), which fuses
the 5′ portion of EWSR1 from chromosome 22 with the
3′ portion of FLI1 from chromosome 11 [8, 9]. EWSR1
encodes the EWS protein, which belongs to the TLS/EWS/
TAF15 (TET) family of putative RNA-binding proteins [10,
11]. Understanding the physiologic roles of TET proteins
has recently become of greater scientific interest as data
continues to surface identifying these members as being
intrinsic to the development of other sarcomas arising
from similar chromosomal translocations. Currently, EWS
has been hypothesized to perform a number of functions,
including, but not limited to: RNA transcription and/or pro-
cessing, neuronal cell differentiation, meiosis, B-lymphocyte
development, and proneural cell survival in the developing
zebrafish embryo [12]. Interestingly, it also appears that EWS
may play an important role in mitotic integrity, which will be
discussed in more detail later [13].
FLI1 encodes FLI, a member of the ETS family of
transcription factors [14]. Wild-type FLI participates in
hematopoietic, vascular, and neural crest development [15–
17]. FLI contains an 85-amino-acid domain in its carboxy-
terminus which mediates sequence-specific DNA binding [8,
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17, 18]. This consensus ets domain recognizes the conserved
core sequence motif GGAA/T, with bases flanking the core
sequence contributing to affinity and specificity [9, 19]. A
total of 27 ETS family members have been identified in the
human genome [17].
The (11;22) chromosomal translocation gives rise to
the fusion protein EWS/FLI. This protein product pairs the
DNA-binding domain of FLI with a strong transcriptional
activation domain from EWS, thereby generating an aber-
rant transcription factor [14, 18]. Many genes have been
identified that are regulated by EWS/FLI, some of which
have been shown to be necessary for the development of
Ewing’s sarcoma [20–28]. Interestingly, recent data suggests
that a significant percentage of deregulated genes are indirect
targets of EWS/FLI, reinforcing the long-held belief that
EWS/FLI-mediated oncogenesis likely involves both direct
and indirect mechanisms of targeted gene deregulation
[19].
Defects in the regulation of normal cell proliferation
are characteristic of all transformed cells [29]. Mutations
affecting genes involved in networks regulating cell cycle
often underlie such uncontrolled proliferation, which sub-
sequently becomes exploited during oncogenesis [30, 31].
Previous data has shown that EWS/FLI is an oncogene.
Therefore, it is likely to mediate alterations in cell cycle,
either alone or in concert with mutations in other genes,
to control cell proliferation in Ewing’s sarcoma. Recently,
data published by Kauer et al. has lent credence to this
belief. Specifically, the authors demonstrated through the
development of a molecular function map of Ewing’s
sarcoma that a large number of EWS/FLI upregulated genes
participate in regulation of the cell cycle [32]. Importantly,
these data were generated using both primary patient-
derived cell lines as well as primary tumor samples obtained
from individuals with Ewing’s sarcoma, suggesting that these
results are correlative with the disease process in vivo.
Consequently, a better understanding of how the cell cycle
is deregulated by EWS/FLI to support uncontrolled cell pro-
liferation will provide critical insight into its overall role in
tumorigenesis.
One major issue that has made studying EWS/FLI-
mediated cell cycle deregulation difficult, however, is the
fact that the cell of origin for Ewing’s sarcoma is unknown.
Consequently, investigators have used various heterologous
systems to determine how EWS/FLI may impinge on the
cell cycle in order to facilitate oncogenesis. Unfortunately,
an inherent problem with this approach is that different
cell types exhibit different levels of tolerance to EWS/FLI
expression. For instance, NIH-3T3 cells expressing EWS/FLI
become transformed whereas YAL-7 cells, a derivative of
NIH-3T3 cells, fail to do so [33]. In addition, expression of
EWS/FLI in primary murine fibroblasts results in cell death
whereas immortalized human fibroblasts undergo a p53-
dependent growth arrest with concomitant downregulation
of several cell cycle regulators [33, 34]. Further confounding
the issue is that comparisons of gene expression profiles
derived from a number of microarray data sets suggested
that heterologous systems do not always recapitulate the
gene expression of human tumors [35, 36]. To circumvent
this problem, many groups have started using patient-
derived Ewing’s sarcoma cell lines [17, 21–23, 28, 32, 37–
40]. Loss of EWS/FLI expression in many of these cell
lines results in growth inhibitory effects [20, 37, 41–44].
Interestingly, however, there does exist one cell line that
does not exhibit such effects, A673. Although initially
characterized erroneously as a rhabdomyosarcoma cell line,
A673 cells have been shown to express EWS/FLI and
recapitulate the gene expression pattern of bona fide Ewing’s
sarcoma [25, 36]. Loss of EWS/FLI expression in A673
cells does not inhibit their proliferation in vitro [25, 45].
Consequently, the use of this particular cell line to study
EWS/FLI-mediated transformation has allowed changes in
cell cycle regulation specific to the oncogenic process to be
identified. By understanding the interplay between EWS/FLI
and regulators of cell cycle one may be able to determine
why such discrepancies in tolerance are seen between
different cell lines and may lead to the identification of
specific conditions permissive to the development of Ewing’s
sarcoma.
2. General Cell Cycle
Cell cycle progression is a highly regulated process. Defects
in the cell cycle machinery can undermine this regulation,
subsequently leading to uncontrolled cell proliferation as
well as genomic and chromosomal instability, all of which
are a prelude to oncogenesis [46, 47]. There are four different
phases of the cell cycle, which can be grouped into two
general processes: interphase and mitosis [48]. Interphase
consists of three distinct phases, referred to as G1, S, and
G2, which are involved in cellular growth and replication of
the genome. During mitosis, or the M phase, cells undergo
the process of division, which culminates in the generation
of two identical daughter cells. As cells exit from mitosis,
they can either re-enter the cell cycle at the G1 phase or be
diverted to the G0 phase where they enter into a quiescent
state.
Cyclin-dependent kinases, or CDKs, are the master regu-
lators of the cell cycle, and it is defects in their function that
often lead to inappropriate cell growth [46, 47]. CDKs are
serine/threonine kinases that, when bound to their respective
cyclin subunits, become activated and phosphorylate RB
[49]. This leads to the dissociation of the transcription factor
E2F from RB, which then allows for the transactivation of
target genes necessary for cell cycle progression. CDK activity
is controlled in multiple ways: the availability of cyclin
subunits, the presence of posttranslational modifications,
and the existence of cyclin-dependent kinase inhibitors,
or CKIs [50]. CKIs play an important inhibitory role in
the cell cycle as they can bind to and repress cyclin-CDK
activity when necessary. Cyclins and CKIs themselves are
regulated by changes in the rate of gene expression and
proteolysis throughout the cell cycle in order to maintain
proper progression. The intricacies of the cell cycle will be
discussed in more detail in the following sections, along
with current data to suggest how EWS/FLI contributes to
its deregulation in facilitating the development of Ewing’s
sarcoma (see Figure 1 for an overview of the cell cycle).
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Figure 1: Overview of the cell cycle. Progression through the cell cycle is mediated by cyclin-CDK complexes that regulate RB function.
Cyclin-dependent kinase inhibitors negatively regulate this process in order to control DNA replication and cell division. Based on the data
presented above, regulators of the cell cycle thought to be involved in Ewing’s sarcoma pathogenesis are indicated. (Note: in an effort to be
concise, only the most significant regulators and their respective functions are included in the diagram).
3. The G1 and S Phases of Cell Cycle
G1 may arguably be the most important phase of the cell
cycle as it is the first line of defense against oncogenic
transformation. Multiple levels exist within the G1 phase to
ensure that cells harboring mutations or other detrimental
aberrations are not allowed to enter S phase. This is extremely
important as once cells have passed through the restriction
(R) point into S phase, they are irreversibly committed to
completing that particular round of cell cycle [48]. The
RB pathway plays an essential role in this process, as it
is the tightly regulated phosphorylation of RB itself that
progression through G1 and into S phase is controlled.
The retinoblastoma gene RB1 encodes the protein prod-
uct RB, which has a molecular weight of approximately
110 kDa [51]. Two other members of the RB family of
proteins, p107 and p130, function similarly to RB, and their
expression/role in cell cycle tends to be cell and context
dependent [52]. It is the phosphorylation status, which
is regulated by extracellular cues, of RB that determines
whether cells progress through the cell cycle. In the presence
of growth factors, mitogenic signaling activates the expres-
sion of D- and E-type cyclins. There are three different D-
type cyclins (i.e., cyclins D1, D2, and D3) and two different
E-type cyclins (i.e., cyclins E1 and E2), all of which exhibit
different tissue-specific patterns of expression [30, 48, 49,
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53]. Cyclin D proteins interact with the cyclin-dependent
kinase CDK4 (or its isoform CDK6 in certain cell types)
whereas cyclin E proteins interact with CDK2, both of
which act as allosteric activators to generate functional kinase
complexes. Initially, the cyclin D-CDK4 complex targets RB
for phosphorylation [54]. Once this has occurred, RB then
becomes a substrate for cyclin E-CDK2. It is following a
second round of phosphorylation by cyclin E-CDK2 that RB
dissociates from the transcription factor E2F, subsequently
facilitating progression through G1 and into S phase of the
cell cycle.
Surprisingly, mutations targeting RB itself are extremely
rare in primary Ewing’s tumors, as are mutations involving
CDK4 gene amplification and/or overexpression of cyclin D1
[49, 55–61]. However, experiments analyzing expression of
cell cycle regulators in the presence and absence of EWS/FLI
have provided additional information as to the mechanisms
being utilized during the development of Ewing’s sarcoma.
For instance, the level of EWS/FLI tends to correlate directly
with the amount of cyclin D1 being expressed [43, 61].
Interestingly, EWS/FLI appears to control even what isoform
of cyclin D1 is present (i.e., cyclin D1b), favoring that which
has been shown to be more oncogenic [40]. Moreover,
EWS/FLI also appears to modulate the level of cyclin
E proteins in order to facilitate accelerated proliferation,
an attribute previously unidentified from tumor sample
analyses [62, 63]. Although it seems that EWS/FLI controls
proliferation by deregulating G1 phase cell cycle regulators,
one must be cautious in interpreting such results. These
data were generated using patient-derived cell lines that
exhibit growth arrest following inhibition of EWS/FLI. As
previously discussed, not all cell lines undergo growth arrest
or change in growth rate with changes in EWS/FLI expression
[25]. Importantly, changes in cyclin levels have not been
consistently observed in such cell lines. Thus, it is not clear
whether a direct cause-effect relationship between EWS/FLI
and cyclin expression exists, or whether such correlations
are due instead to growth effects mediated through other
EWS/FLI-dependent pathways.
The activity of CDK4/6 is negatively regulated by a
set of cyclin-dependent kinase inhibitors belonging to the
INK4 family of proteins (a second CKI family is involved
in the regulation of CDK2, which will be discussed in more
depth later in the paper). There are four members of the
INK4 family, which include INK4A (or p16), INK4B (or
p15), INK4C (or p18), and INK4D (or p19) [31, 48, 57].
These CKIs are small proteins that act to inhibit kinase
activity in two ways: (1) by binding to CDK4/6, preventing
association with D-type cyclins and (2) by interacting with
the catalytic cleft of CDK4/6, thus inhibiting the binding
of ATP molecules required for the phosphorylation of its
substrates [64]. Consequently, the presence of INK4 CKIs
results in the inability of CDK4/6 to phosphorylate RB, thus
inhibiting progression in the G1 phase of the cell cycle.
The most frequent genetic aberration associated with
Ewing’s sarcoma involves deletion of the CDKN2A locus,
which results in functional loss of the p16 gene [59].
Interestingly, the gene encoding p15 (CDKN2B) maps to the
same chromosomal region as CDKN2A, and so deletions
present in cancer cells involving CDKN2A often also affect
CDKN2B, resulting in functional loss of both p16 and
p15. Approximately 10–30% of all primary Ewing’s tumors
exhibit either homozygous or hemizygous deletion of the
CDKN2A gene and sometimes also deletion of the CDKN2B
gene [10, 49, 55, 57, 65–67]. Importantly, a number of
analyses have shown that individuals with this particular
mutation exhibit a statistically significant correlation with
poor overall survival, but not with metastatic presence or
chemotherapeutic response [60, 68, 69].
One interesting characteristic of Ewing’s tumors is that
the frequencies of genetic aberrations described above tend
to be much different in patient-derived primary Ewing’s
sarcoma cell lines. This is evidenced by the fact that more
than 50% of all cell lines appear to exhibit loss of functional
p16. Deletions of the CDKN2A locus as well as hypermethy-
lation of the gene promoter both appear to contribute to this
type of mutation with the latter being almost nonexistent in
primary tumor samples [10, 57]. It is not entirely understood
why such a discrepancy exists, but the fact that deletion of
CDKN2A is the most prevalent mutation associated with
Ewing’s sarcoma suggests an important role for the alteration
in at least a subset of Ewing’s sarcoma.
Following dissociation of the transcription factor E2F
from its inhibitory interaction with RB, expression of target
genes required for cells to progress through S phase occurs.
Included in this is the expression of A-type cyclins [30,
48]. There are two different A-type cyclins, cyclin A1 and
cyclin A2 [70, 71]. Cyclin A1 expression is restricted to
cells in the developing embryo as well as those undergoing
meiosis. However, cyclin A2 is ubiquitously expressed in all
proliferating somatic cells, thus acting as the main A-type
cyclin involved in cell cycle processes. Cyclin A2 associates
with CDK2 and activates its kinase function, subsequently
facilitating the phosphorylation of target proteins required
for S phase progression. Most importantly, the cyclin A2-
CDK2 complex has been shown to play a vital role in the
process of DNA replication [72]. Interestingly, no studies to
date have identified mutations or alterations involving cyclin
A2 or CDK2 that could contribute to the process of Ewing’s
sarcoma oncogenesis.
4. The G2 and M Phases of Cell Cycle
Following the completion of DNA replication, cells exit S
phase and enter the G2 phase of cell cycle. At this point,
cyclin A2 becomes associated with a second cyclin-dependent
kinase, CDK1 (also referred to as CDC2) [31, 50]. The role of
cyclin A2-CDK1 is to facilitate the transition from G2 to the
mitotic phase of the cell cycle, specifically by regulating the
activity and degradation of proteins involved in this process
[73]. Regulation at this transition point in the cell cycle
ensures that only cells with a full complement of intact DNA
are allowed to divide. Absence of such regulation can result
in oncogenesis via any number of mechanisms, including the
deletion of a single gene, parts of or whole chromosomes,
and even aberrant chromosomal fusions, as is seen with
Ewing’s sarcoma [48].
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In order to progress through mitosis, cells rely on
the presence of B-type cyclins. There are three different
family members, including cyclins B1, B2, and B3. Cyclin
B3 is expressed mainly in meiotic cells in embryonic and
adult tissues whereas cyclins B1 and B2 are more generally
expressed in somatic cells [74]. In addition, cyclin B2
localizes to the Golgi while cyclin B1 is found mainly within
the nucleus, thus acting as the major B-type cyclin involved
in mitosis. At the beginning of prophase, cyclin B1-CDK1
complexes form in order to phosphorylate (and in some cases
activate) proteins involved in the progression of mitosis [75].
In order for cells to enter anaphase, CDK1 and cyclin B1
are degraded, followed by completion of cell division. At this
point, cells are able to exit mitosis, thus facilitating a second
round of cell cycle.
Currently there are no published studies to suggest that
cyclins or CDKs involved in G2 and M phase of the cell cycle
are deregulated in primary Ewing’s tumor samples. However,
a few studies have identified other components of the path-
way that EWS/FLI may target to control the cell cycle. For
example, EWS/FLI appears to upregulate expression of the
murine homolog of human EZ-C/UbcH10, a cyclin-specific
ubiquitin conjugating enzyme [76]. Increased levels of this
protein were shown to enhance the destruction of mitotic
cyclins as well as inhibit CDK1 activity, thus promoting
the onset of anaphase and mitotic exit. Consequently, cells
are able to progress through mitosis more quickly and to
continually re-enter the cell cycle, thus resulting in continued
proliferation. Lack of regulation during mitosis can lead to
oncogenesis as checkpoints normally present in the cell that
act to prevent aberrant exit, and re-entry may cause cells with
missing/damaged DNA to continue to proliferate.
Recently it has been suggested that wild-type EWS plays
an important role in mitotic spindle formation and that the
presence of EWS/FLI interferes with this function by acting
in a dominant-negative fashion [13]. Specifically, Embree et
al. demonstrated using both a zebrafish model system as well
as HeLa cells that ectopic expression of EWS/FLI results in
cells exhibiting gross mitotic spindle defects. Interestingly,
loss of wild-type EWS produced the same phenotype.
Further experiments showed that abnormal localization of
aurora kinase B preceded the presence of spindle defects
in cells, suggesting that under normal conditions wild-type
EWS plays a role in facilitating proper localization of aurora
kinase B during mitosis. Another group has also suggested
that aurora kinases A and B are transcriptionally modulated
by EWS/FLI [77]. Additional data is needed, however, to
show that disruption of mitotic spindle formation is a
means by which EWS/FLI modulates the cell cycle in the
pathogenesis of Ewing’s sarcoma.
5. Broad Regulators of Cell Cycle
5.1. The p53-ARF-MDM2 Pathway. In conjunction with the
CDK4/6 inhibitor p16INK4A, mutations of the TP53 gene
are the most recurrent genetic alterations associated with
cancer [49]. The TP53 gene encodes the well-known tumor-
suppressor p53, which plays an important role in various
regulatory processes involved with cell cycle progression.
Most importantly, p53 acts as a negative regulator, facil-
itating growth arrest, senescence, and/or apoptosis when
cells are exposed to genotoxic, cytotoxic, and/or physiologic
stresses [78, 79]. p53 is a transcription factor possessing
two transcriptional activation domains and a DNA-binding
domain that recognizes specific sequences. Following expo-
sure to cellular stress, p53 activates expression of CDKN1A,
which encodes the cyclin-dependent inhibitor p21CIP1. It
is through the expression of p21 (and other transcriptional
targets) that p53 negatively regulates the cell cycle (a more
detailed discussion of this particular CKI and the family of
proteins it belongs to will be provided in the next section)
[64, 80–82].
The expression level and activity of p53 is regulated by
two different proteins: MDM2 and p14ARF. MDM2 is an
E3 ubiquitin ligase, which facilitates the degradation of p53
in a ubiquitin- and proteasome-dependent manner [83].
Interestingly,MDM2 is a transcriptional target of p53, whose
expression is increased in concert with increased levels of
p53 [84]. In addition to promoting degradation, MDM2 can
also inhibit p53 function through a direct protein-protein
interaction, suppressing its transcriptional activity, as well as
translation of the mRNA transcript itself. In order to combat
these negative regulatory effects, p14ARF is able to positively
regulate p53, in part through the negative regulation of
MDM2. p14ARF is actually found at the same genetic locus
as CDKN2A, which encodes the CKI p16 [39, 84]. The
two gene sequences overlap but possess alternate reading
frames and are independently regulated. ARF binds MDM2,
preventing it from interacting with p53 [78]. Consequently,
p53 becomes stabilized, and its overall activity increases
within the cell [67].
Although more than half of all primary patient-derived
Ewing’s sarcoma cell lines possess direct p53 loss-of-function
mutations, only about 5–20% of Ewing’s tumors exhibit
similar genetic defects [10, 19, 49, 57, 66, 67, 81, 83, 85].
Yet, many of these studies have shown that patients harboring
p53 mutations not only have a significantly poorer outcome
with respect to both disease-free and overall survival but
also have a higher probability of relapse [66, 81, 86–88].
Mutations in MDM2 seem to be extremely rare in Ewing’s
tumors [10, 56, 60]. However, since a large percentage of
Ewing’s tumors exhibit deletion of the CDKN2A locus, it
is likely that they also harbor deletions in p14ARF [89].
Consequently, targeted disruption of TP53 may not be as
important for the pathogenesis of Ewing’s sarcoma as is
general inhibition of the p53 pathway.
Identifying genetic aberrations present in both tumor
samples and cell lines may provide information necessary to
understand how EWS/FLI mediates Ewing’s sarcoma onco-
genesis. One important example of this is the discrepancy
seen with respect to p53 loss-of-function mutations. Previ-
ous experiments have shown that increased expression of
EWS/FLI results in an increase in p53 expression, as well as an
increased apoptotic response following irradiation [90]. In
addition, ectopic expression of the fusion protein in various
primary cell lines, including human foreskin fibroblasts,
has been shown to cause p53-mediated growth arrest [34].
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These results indicate that in order for EWS/FLI to induce
transformation, the p53 pathway must be deregulated in
some way. Thus, it is likely that primary tumors expressing
wild-type p53 harbor other genetic abnormalities yet to be
identified that impinge on other aspects of the p53 pathway.
Understanding how the p53 pathway is modulated in Ewing’s
sarcomamay help to increase the efficacy of therapies used to
combat the malignancy as most chemotherapy and radiation
treatments induce cancer cell death in a p53-dependent
manner [79].
5.2. The CIP/KIP Family of CKIs. As was discussed ear-
lier, there is a second family of cyclin-dependent kinase
inhibitors, referred to as the CIP/KIP family of proteins
[30]. There are three different members: p21CIP1, p27KIP1,
and p57KIP2. Similar to the INK4 family of CKIs, CIP/KIP
proteins inhibit the kinase activity of CDKs by preventing
their association with cyclin subunits and ATP molecules,
both of which are required for the phosphorylation of
target substrates [48, 64]. Unlike the INK4 family, however,
CIP/KIP proteins are able to functionally inhibit multiple
CDKs. For instance, both p27 and p57 can inhibit the
kinase activity of CDK4/6 and CDK2 whereas p21 acts
to control the function of both CDK2 as well as CDK1
[31, 80]. Of the three family members, p21 is the most
diverse, performing a variety of functions in addition to
controlling CDK activity. For example, it was previously
mentioned that p21 is a transcriptional target of p53 [64, 80–
82, 91]. Following exposure to various stresses, p53 activates
the expression of p21, thus contributing to a DNA damage
response [80]. In addition, p21 has been shown to localize
to the cytoplasm where it acts to inhibit the induction of
apoptosis by interacting with proteins involved in mediating
this process.
Most of the data acquired to date regarding the role
of CIP/KIP proteins in Ewing’s sarcoma oncogenesis have
come from experiments using cell lines. However, a few
pieces of in vivo data do exist that corroborate the in vitro
findings. For instance, loss of p21 and p27 expression has
been seen in both formalin-fixed paraffin-embedded (FFPE)
and primary tumor samples [58, 62, 92]. Importantly,
FFPE samples exhibiting decreased levels of p21 and p27
came from patients that exhibited a significantly shorter
overall rate of survival. Interestingly, however, similar results
were not seen with respect to the primary tumor samples
analyzed. In addition, EWS/FLI has been shown to inhibit
the expression of these two proteins in various cell lines,
with EWS/FLI levels correlating inversely with those of p21
and p27 [43, 44, 93]. Furthermore, while one group has
demonstrated that p21 may be a direct transcriptional target
of EWS/FLI, identification of an in vivo binding site has thus
far alluded investigators [94]. Unlike p21, however, there
is currently no data to suggest that p27 is a direct target
of EWS/FLI-mediated deregulation. Surprisingly, very little
data exists to suggest that p57 contributes to the oncogenic
process of Ewing’s sarcoma. Yet, one group did identify
that expression of EWS/FLI correlates inversely with p57
expression similar to that found for p21 and p27 [38].
Consequently, it is possible that genetic alterations targeting
these CIP/KIP family members could act as a mechanism
for EWS/FLI-mediated transformation in the development
of Ewing’s sarcoma. However, further studies are required to
understand the biological significance of these results.
5.3. Additional Regulators. The last two cell cycle regulators
that will be discussed in this paper are C-MYC and Ki67.
Both of these proteins play crucial roles during cell prolif-
eration but do so in very different ways. C-MYC influences
several processes involved in cell cycle regulation via its
function as a transcription factor. For example, C-MYC,
when bound to its partner MAX, has been shown to induce
the expression of cyclins D1 and D2 as well as CDK4,
subsequently promoting G1 phase progression [48, 95]. The
MYC-MAX heterodimer can also support continued cell
cycle progression through the repression of multiple CKIs,
including p15, p18, p21, and p27 [96]. Furthermore, C-MYC
can increase the expression of E2F2 and cyclin A2, both
of which effect the S phase of cell cycle and contribute to
overall proliferation [96–98]. Similar to C-MYC, Ki67 has
been shown to be vital for cell proliferation [99]. Ki67 is a
cell proliferation-associated nuclear antigen that is thought
to contribute to cell cycle progression via its involvement in
rRNA and ribosome synthesis [99, 100]. Interestingly, Ki67 is
expressed in all of the phases of cell cycle (excluding G0), but
whether or not it participates in other such related processes
is currently unknown.
Directly or indirectly, C-MYC activity appears to be
deregulated in almost all tumor cells [95]. Experiments using
primary patient-derived Ewing’s sarcoma cell lines have
indicated that C-MYC is a gene target of EWS/FLI [38, 93,
101, 102]. However, efforts to identify a bona fide EWS/FLI
binding site have proved unsuccessful. Expression levels of
the fusion protein appear to correlate directly with those of
C-MYC, resulting in an overall increase in cell proliferation.
Nonetheless, this conclusion is somewhat controversial, as
experiments demonstrating this relationship are found only
to exist under conditions where loss of EWS/FLI expression
inhibits cell growth, raising the question of whether this
result is limited to particular experimental conditions or is
specific to the disease process. Interestingly, it has also been
shown that EWS/FLI expression increases the levels of ID2,
or inhibitor of DNA binding 2. ID2 is the dominant-negative
form of a basic helix-loop-helix transcription factor, which
lacks a functional DNA-binding domain. ID2 contributes
to C-MYC-induced cell proliferation by interacting with
RB, ultimately suppressing its ability to inhibit cell cycle
progression. Primary tumor samples also appear to exhibit
increased ID2 expression, but the biological implications of
these results with respect to the development of Ewing’s
sarcoma are currently unknown.
Intriguingly, primary Ewing tumor samples have been
shown to exhibit a significant correlation between C-MYC
expression and the percent of cells positive for Ki67, which
acts as a measure of overall proliferation [67, 103]. Patients
exhibiting a higher Ki67 positivity tended to have a better
chemotherapeutic response, as measured by the amount of
tumor necrosis following initial treatment [87]. However
there are conflicting results as to whether or not Ki67
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positivity correlates with a worse prognosis [103]. Ki67
positivity is used as both a prognostic and diagnostic tool for
other malignancies, however, suggesting that further studies
should be conducted in order to determine if such use is also
applicable to Ewing’s sarcoma [99].
6. Conclusion
Ewing’s sarcoma is a highly aggressive disease with a relatively
low survival rate. Determining how deregulation of the
cell cycle contributes to the oncogenic process has led
to an increased understanding of Ewing’s sarcoma devel-
opment (see Figure 1). However, many questions remain
unanswered. For instance, does a single mutation explain
deregulation of the cell cycle in Ewing’s sarcoma? The
most common genetic alteration associated with Ewing’s
tumors involves deletion of CDKN2A, which encodes the
p16 and p14 proteins. Yet, only about one-third of all
tumors actually possess such mutations. In addition, the
second most frequent aberration identified to be associated
with Ewing’s sarcoma involves mutation of TP53. Again,
however, less than one-fourth of all Ewing’s tumors actually
possess a mutant form of p53. The remaining genetic
alterations found to facilitate deregulation of the cell cycle
in Ewing’s sarcoma are even rarer. Moreover, differences in
mutational frequencies between primary tumors and cell
lines have further complicated the issue of identifying genetic
alterations specific to the disease process. Consequently,
no single mutation has been identified that appears to
specifically mediate deregulation of the cell cycle in Ewing’s
sarcoma.
Although no individual mutation has been identified to
explain how the cell cycle is deregulated in Ewing’s sarcoma,
most tumors contain genetic alterations that specifically
affect the activity of cyclin-dependent kinase inhibitors. For
instance, mutations in CDKN2A and CDKN2B result in
functional loss of p16 and p15, respectively. In addition,
deactivating mutations in p14ARF (often resulting from
deletions in CDKN2A) and p53 as well as amplification of
MDM2 all lead to functional loss of p21. Those mutations
affecting positive cell cycle regulators such as cyclins and
CDKs occur much less frequently and often have only been
identified in in vitro experiments using patient-derived cell
lines. Consequently, it is possible that underlying Ewing’s
sarcoma development is the inactivation of CKIs, a common
mechanism by which the cell cycle is deregulated.
Since no common mechanism of cell cycle deregula-
tion in Ewing’s sarcoma has been identified, it raises the
question of whether or not EWS/FLI contributes to its
deregulation. Currently there is no clear answer, as most
EWS/FLI-mediated changes in cell cycle regulation have been
identified solely under particular experimental conditions
where inhibition of EWS/FLI expression elicits growth
arrest. However, it is important to point out that EWS/FLI
must have some effect on the cell cycle since previous
experiments have shown that mutations in specific regulators
(such as p53) are often required to create a permissive
environment for EWS/FLI expression. In addition, some type
of mutation affecting cell cycle regulation is present in a large
percentage of primary Ewing’s tumors analyzed, suggesting
that EWS/FLI activity does trigger cell cycle inhibitory
pathways and that these pathways must be bypassed prior to
tumor development. Thus, although not fully understood,
it does appear that EWS/FLI contributes to uncontrolled
cell proliferation by affecting pathways involved in cell cycle
control.
Identification of EWS/FLI as being necessary for the
development of this malignancy has provided great insight
into some of the molecular mechanisms that underlie the
oncogenic process. However, despite the fact that EWS/FLI
is necessary for Ewing’s sarcoma pathogenesis, other coop-
erating mutations are required. Such cooperating mutations
appear to target components of the cell cycle in order to
facilitate uncontrolled cell proliferation. The different genetic
aberrations currently known have been summarized above.
However, there is no single genetic alteration yet discovered
that would suggest a specific mechanism being employed
during tumor development. Future experiments attempting
to understand how cell cycle deregulation contributes to
the oncogenesis of Ewing’s sarcoma will hopefully provide
greater insight into the disease process, thus leading to more
efficacious treatment therapies that can be used to combat
this disease.
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